|

ASTX727 Clinical Trials

7 actively recruiting trials across 3 locations

▼ -1 trial since August 2026

Also known as: C-DEC, INQOVI, Inqovi, Oral decitabine and cedazuridine

Pipeline

Phase 1: 5Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Taiho Oncology, Inc.2
  • M.D. Anderson Cancer Center2
  • Memorial Sloan Kettering Cancer Center1
  • Massachusetts General Hospital1
  • Imperial College London1

Indications

  • Cancer7
  • Acute Myeloid Leukemia4
  • Myelodysplastic Syndromes2
  • Neurological Cancer1
  • Malignant Peripheral Nerve Sheath Tumors (MPNST)1

Houston, Texas4 trials

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

M D Anderson Cancer Center

Phase 1/2
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

MD Anderson Cancer Center

Phase 1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

MD Anderson

Phase 1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

MD Anderson

Phase 1

Other1 trial

Lutathera and ASTX727 in Neuroendocrine Tumours
Phase 1

Boston, Massachusetts1 trial

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Massachusetts General Hospital Cancer Center

Phase 1

Basking Ridge, New Jersey1 trial

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.